Tobira Therapeutics

CELL AND GENE THERAPY

AbbVie | February 11, 2021

AbbVie and Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome altering biotechnology organization, reported today that they have gone into a cooperation and permit arrangement for the innovative work of fanciful antigen receptor (CAR)- T cell therapeutics. Albeit allogeneic, "off-the-shelf" CAR-T cell therapies have indicated early guarantee in some malignancy patients, the requirement for beating the dismissal of allogeneic CAR-T cells by the host immune system stays a ...

CELL AND GENE THERAPY

Ocean Genomics, Geninus Inc | March 30, 2021

Ocean Genomics (Pittsburgh, PA), a world chief in AI-based gene expression analysis and RNA biomarker development, and Geninus (Seoul, South Korea), a main full-administration genomics laboratory, report an essential association with the end goal of co-creating RNA-based biomarkers and propelling exploration and clinical applications with emergency clinic, scholastic and biotechnology customers. The two organizations will dispatch in Korea Ocean Genomics' high level AI-based t...

MEDICAL

Carbosynth | May 30, 2022

Biosynth Carbosynth (“Biosynth”), a supplier of critical materials to the life science industry, announces today the acquisition of Aalto Bio Reagents (“Aalto”), a leading developer and provider of biological materials to the in-vitro diagnostic (IVD) and vaccine development industry in the field of emerging disease. The acquisition represents a further milestone in Biosynth’s development, which broadens its capabilities and offering to the IVD indust...

PharmaMar | April 28, 2020

PharmaMar (MSE: PHM) has announced the start of the APLICOV-PC clinical trial with Aplidin® (plitidepsin), for the treatment of patients with COVID-19, which has been authorized by the Spanish Medicines and Healthcare Products Agency (AEMPS). This is a multicenter, randomized, parallel, open-label study to evaluate the safety profile and efficacy of three doses of plitidepsin in patients with COVID-19 requiring hospital admission. Three hospitals from Madrid (Spain) will participate in the s...